PHAXIAM Therapeutics S.A. (PHXM) - Net Assets
Based on the latest financial reports, PHAXIAM Therapeutics S.A. (PHXM) has net assets worth €15.45 Million EUR (≈ $18.06 Million USD) as of June 2024. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€39.11 Million ≈ $45.72 Million USD) and total liabilities (€23.66 Million ≈ $27.66 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check PHXM capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €15.45 Million |
| % of Total Assets | 39.5% |
| Annual Growth Rate | 15.39% |
| 5-Year Change | -70.07% |
| 10-Year Change | -28.51% |
| Growth Volatility | 140.29 |
PHAXIAM Therapeutics S.A. - Net Assets Trend (2010–2023)
This chart illustrates how PHAXIAM Therapeutics S.A.'s net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see how much is PHAXIAM Therapeutics S.A. worth.
Annual Net Assets for PHAXIAM Therapeutics S.A. (2010–2023)
The table below shows the annual net assets of PHAXIAM Therapeutics S.A. from 2010 to 2023. Also explore PHXM net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | €25.61 Million ≈ $29.94 Million |
+9.05% |
| 2022-12-31 | €23.49 Million ≈ $27.46 Million |
+2.81% |
| 2021-12-31 | €22.84 Million ≈ $26.71 Million |
-13.92% |
| 2020-12-31 | €26.54 Million ≈ $31.03 Million |
-68.98% |
| 2019-12-31 | €85.56 Million ≈ $100.03 Million |
-41.24% |
| 2018-12-31 | €145.60 Million ≈ $170.22 Million |
-19.74% |
| 2017-12-31 | €181.42 Million ≈ $212.10 Million |
+409.06% |
| 2016-12-31 | €35.64 Million ≈ $41.66 Million |
-24.39% |
| 2015-12-31 | €47.13 Million ≈ $55.10 Million |
+31.56% |
| 2014-12-31 | €35.82 Million ≈ $41.88 Million |
+163.67% |
| 2013-12-31 | €13.59 Million ≈ $15.88 Million |
+437.39% |
| 2012-12-31 | €-4.03 Million ≈ $-4.71 Million |
-111.28% |
| 2011-12-31 | €-1.91 Million ≈ $-2.23 Million |
-147.82% |
| 2010-12-31 | €3.99 Million ≈ $4.66 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to PHAXIAM Therapeutics S.A.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2348800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €6.08 Million | 23.72% |
| Other Comprehensive Income | €-6.65 Million | -25.95% |
| Other Components | €49.67 Million | 193.94% |
| Total Equity | €25.61 Million | 100.00% |
PHAXIAM Therapeutics S.A. Competitors by Market Cap
The table below lists competitors of PHAXIAM Therapeutics S.A. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Prostatype Genomics AB
ST:PROGEN
|
$1.01 Million |
|
River and Mercantile UK Micro Cap Investment Company Ltd
LSE:RMMC
|
$1.01 Million |
|
Wynnstay Group Plc
LSE:WYN
|
$1.02 Million |
|
General Shopping e Outlets do Brasil S.A.
SA:GSHP3
|
$1.02 Million |
|
BioNeutra Global Corp
V:BGA
|
$1.01 Million |
|
The Alumasc Group plc
LSE:ALU
|
$1.01 Million |
|
GACM Technologies Limited
NSE:GATECHDVR
|
$1.01 Million |
|
Venture Life Group PLC
LSE:VLG
|
$1.00 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PHAXIAM Therapeutics S.A.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 23,487,000 to 25,612,000, a change of 2,125,000 (9.0%).
- Net loss of 23,488,000 reduced equity.
- Other comprehensive income increased equity by 21,944,000.
- Other factors increased equity by 3,669,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-23.49 Million | -91.71% |
| Other Comprehensive Income | €21.94 Million | +85.68% |
| Other Changes | €3.67 Million | +14.33% |
| Total Change | €- | 9.05% |
Book Value vs Market Value Analysis
This analysis compares PHAXIAM Therapeutics S.A.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.02x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | €2.90 | €0.10 | x |
| 2014-12-31 | €6.10 | €0.10 | x |
| 2015-12-31 | €6.77 | €0.10 | x |
| 2016-12-31 | €4.46 | €0.10 | x |
| 2017-12-31 | €147.46 | €0.10 | x |
| 2018-12-31 | €75.02 | €0.10 | x |
| 2019-12-31 | €44.09 | €0.10 | x |
| 2020-12-31 | €13.34 | €0.10 | x |
| 2021-12-31 | €8.91 | €0.10 | x |
| 2022-12-31 | €7.00 | €0.10 | x |
| 2023-12-31 | €5.46 | €0.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently PHAXIAM Therapeutics S.A. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -91.71%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1771.34%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 2.00x
- Recent ROE (-91.71%) is below the historical average (-81.88%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -59.94% | -451.92% | 0.10x | 1.32x | €-9.50 Million |
| 2014 | -24.73% | -493.60% | 0.04x | 1.13x | €-12.44 Million |
| 2015 | -31.85% | -512.56% | 0.06x | 1.12x | €-19.73 Million |
| 2016 | -61.77% | -531.95% | 0.09x | 1.26x | €-25.58 Million |
| 2017 | -18.48% | -996.73% | 0.02x | 1.08x | €-51.67 Million |
| 2018 | -26.25% | -859.55% | 0.03x | 1.15x | €-52.78 Million |
| 2019 | -73.23% | -1186.05% | 0.04x | 1.39x | €-71.22 Million |
| 2020 | -276.20% | -1971.49% | 0.05x | 3.03x | €-75.95 Million |
| 2021 | -235.49% | -1287.01% | 0.06x | 2.92x | €-56.08 Million |
| 2022 | -0.97% | -3.43% | 0.15x | 1.95x | €-2.58 Million |
| 2023 | -91.71% | -1771.34% | 0.03x | 2.00x | €-26.05 Million |
Industry Comparison
This section compares PHAXIAM Therapeutics S.A.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $28,644,502
- Average return on equity (ROE) among peers: -86.13%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PHAXIAM Therapeutics S.A. (PHXM) | €15.45 Million | -59.94% | 1.53x | $1.01 Million |
| Abionyx Pharma SA (ABNX) | $7.42 Million | -59.27% | 0.81x | $68.88 Million |
| Abivax SA (ABVX) | $196.01 Million | -75.37% | 0.67x | $8.82 Billion |
| Adocia (ADOC) | $10.69 Million | -44.27% | 0.41x | $83.81 Million |
| Aelis Farma SA (AELIS) | $898.00K | 63.92% | 30.53x | $15.30 Million |
| Biophytis S.A. (ALBPS) | $5.71 Million | -587.66% | 5.36x | $2.38 Million |
| Cellectis (ALCLS) | $75.87 Million | -92.72% | 3.28x | $114.74 Million |
| Advicenne (ALDVI) | $-10.62 Million | 0.00% | 0.00x | $12.61 Million |
| Genoway (ALGEN) | $-1.57 Million | 0.00% | 0.00x | $31.09 Million |
| Integragen (ALINT) | $3.09 Million | -65.97% | 1.25x | $746.14K |
| Medesis Pharma SA (ALMDP) | $-1.06 Million | 0.00% | 0.00x | $1.80 Million |
About PHAXIAM Therapeutics S.A.
PHAXIAM Therapeutics S.A., a clinical-stage biopharmaceutical company, focuses on developing bacteriophage-based therapies for severe resistance infections in France. The company develops and commercializes red cell-based therapies for cancers and orphan diseases. It develops anti-infectious therapies based on the use of bacteriophages (phages) to treat infections caused by Escherichia coli (E.co… Read more